Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial results report.
| Capital Metric | Value as of 30 Sep 2010 |
|---|---|
| Issued Ordinary Shares (25p each) | 5,667,896,232 |
| Treasury Shares | 474,194,158 |
| Total Voting Rights | 5,193,702,074 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document focuses solely on the current share capital composition.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The primary purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights is 5,193,702,074 as of September 30, 2010.
- Confirm that 474,194,158 shares are held in Treasury and excluded from voting rights calculations.
- Note that this filing does not contain financial performance data for the period.